神经阻滞剂恶性综合征

Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164:870-876.

• 摘要

Keck PE Jr, Pope HG Jr, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome: a case-control study. Arch Gen Psychiatry. 1989;46:914-918.

• 摘要

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.

Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989;146:717-725.

• 摘要

World Health Organization. International statistical classification of diseases and related health problems, 10th revision. Diseases of the nervous system: extrapyramidal and movement disorders (G20-G26). 2016. http://apps.who.int/ (last accessed 9 May 2017).

• 全文

1.  Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164:870-876.

• 摘要

2.  Buckley P, Adityanjee M, Sajatovic M. Neuroleptic malignant syndrome. In: Katirji B, Kaminski HJ, Preston DC, et al, eds. Neuromuscular disorders in clinical practice. Boston, MA: Butterworth-Heinemann; 2002:1264-1275.

3.  Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77:185-202.

• 摘要

4.  Lazarus A, Mann SC, Caroff SN. The neuroleptic malignant syndrome and related conditions. Washington, DC: American Psychiatric Press; 1989.

5.  Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry. 1998;155:1113-1116.

• 摘要

6.  Levinson DF, Simpson GM. Neuroleptic-induced extrapyramidal symptoms with fever: heterogeneity of the 'neuroleptic malignant syndrome'. Arch Gen Psychiatry. 1986:43:839-848.

• 摘要

7.  Wargo KA, Gupta R. Neuroleptic malignant syndrome: no longer exclusively a "neuroleptic" phenomenon. J Pharm Technol. 2005;21:262-270.

8.  Angelopoulos P, Markopoulou M, Kyamidis K, et al. Neuroleptic malignant syndrome without fever after addition of oxcarbazepine to long-term treatment with amisulpride. Gen Hosp Psychiatry. 2008;30:482-484.

• 摘要

9.  Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008;42;1290-1297.

• 摘要

10.  Picard LS, Lindsay S, Strawn JR, et al. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy. 2008;28:530-535.

• 摘要

11.  Velamoor VR, Fernando ML, Williamson P. Incipient neuroleptic malignant syndrome? Br J Psychiatry. 1990;156:581-584.

• 摘要

12.  Sewell DD, Jeste DV. Distinguishing neuroleptic malignant syndrome (NMS) from NMS-like acute medical illnesses: a study of 34 cases. J Neuropsychiatry Clin Neurosci. 1992;4:265-269.

• 摘要

13.  Velamoor VR, Norman RM, Caroff SN, et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 1994;182:168-173.

• 摘要

14.  Gurrera RJ, Simpson JC, Tsuang MT. Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence. Compr Psychiatry. 2007;48:205-211.

• 摘要

15.  Nielsen RE, Wallenstein Jensen SO, et al. Neuroleptic malignant syndrome - an 11-year longitudinal case-control study. Can J Psychiatry. 2012;57:512-518.

• 摘要

16.  Takubo H, Harada T, Hashimoto T, et al. A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. Parkinsonism Relat Disord. 2003;9(suppl 1):S31-S41.

• 摘要

17.  Pope HG Jr, Keck PE Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry. 1986;143:1227-1233.

• 摘要

18.  Keck PE Jr, Pope HG Jr, McElroy SL. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry. 1991;148:880-882.

• 摘要

19.  Neuhut R, Lindenmayer JP, Silva R. Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review. J Child Adolesc Psychopharmacol. 2009;19:415-422.

• 全文
• 摘要

20.  Nakamura M, Yasunaga H, Miyata H, et al. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination Database. J Clin Psychiatry. 2012;73:427-430.

• 摘要

21.  Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology. 1981;31:132-137.

• 摘要

22.  Hashimoto T, Tokuda T, Hanyu N, et al. Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson’s disease. Parkinsonism Relat Disord. 2003;9(suppl 1):S25-S30.

• 摘要

23.  Heiman-Patterson TD. Neuroleptic malignant syndrome and malignant hyperthermia: important issues for the medical consultant. Med Clin North Am. 1993;77:477-492.

• 摘要

24.  Gurrera RJ. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia? Clin Neuropharmacol. 2002;25:183-193.

• 摘要

25.  Rosebush PI, Mazurek MF. Serum iron and neuroleptic malignant syndrome. Lancet. 1991;338:149-151.

• 摘要

26.  Rosebush PI, Anglin RE, Richards C, et al. Neuroleptic malignant syndrome and the acute phase response. J Clin Psychopharmacol. 2008;28:459-461.

• 摘要

27.  Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry. 1999;156:169-180.

• 摘要

28.  Trollor JN, Chen X, Chitty K, et al. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry. 2012;201:52-56.

• 全文
• 摘要

29.  Mizuno Y, Takubo H, Mizuta E, et al. Malignant syndrome in Parkinson’s disease: concept and review of the literature. Parkinson Rel Disord. 2003;9(Suppl 1):S3-S9.

• 摘要

30.  Sachdev P, Mason C, Hadzi-Pavlovic D. Case-control study of neuroleptic malignant syndrome. Am J Psychiatry. 1997;154:1156-1158.

• 摘要

31.  Keck PE Jr, Pope HG Jr, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome: a case-control study. Arch Gen Psychiatry. 1989;46:914-918.

• 摘要

32.  Fink M. Neuroleptic malignant syndrome and catatonia: one entity or two? Biol Psychiatry. 1996;39:1-4.

• 摘要

33.  Mall GD, Hake L, Benjamin AB, et al. Catatonia and mild neuroleptic malignant syndrome after initiation of long-acting injectable risperidone: case report. J Clin Psychopharmacol. 2008;28:572-573.

• 摘要

34.  Reulbach U, Dütsch C, Biermann T, et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care. 2007;11:R4.

• 全文
• 摘要

35.  Gurrera RJ, Caroff SN, Cohen A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011;72:1222-1228.

• 摘要

36.  American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.

37.  Marshall PB, Mellman TA, Nguyen SX. Neuroleptic malignant syndrome with the addition of aripiprazole to olanzapine. Am J Psychiatry. 2008;165:1488-1489.

• 摘要

38.  Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry. 2008;69:1157-1165.

• 摘要

39.  Berardi D, Amore M, Keck PE Jr, et al. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry. 1998;44:748-754.

• 摘要

40.  Viejo LF, Morales V, Punal P, et al. Risk factors in neuroleptic malignant syndrome: a case-control study. Acta Psychiatr Scand. 2003;107:45-49.

• 摘要

41.  Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989;146:717-725.

• 摘要

42.  Groff K, Coffey BJ. Psychosis or atypical neuroleptic malignant syndrome in an adolescent? J Child Adolesc Psychopharmacol. 2008;18:529-532.

• 摘要

43.  Keshevan MS, Stecker J, Kambhampati RK. Creatine kinase elevations with clozapine. Br J Psychiatry. 1994;164:118-120.

• 摘要

44.  Bilanakis N, Peritogiannis V, Kalampokis G. Infections as complications of neuroleptic malignant syndrome. World J Biol Psychiatry. 2008;18:1-4.

• 摘要

45.  Perry PJ, Wilborn CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry. 2012;24:155-162.

• 摘要

46.  World Health Organization. International statistical classification of diseases and related health problems, 10th revision. Diseases of the nervous system: extrapyramidal and movement disorders (G20-G26). 2016. http://apps.who.int/ (last accessed 9 May 2017).

• 全文

47.  Yacoub A, Kohen I, Caraballo A, et al. Rating scale for neuroleptic malignant syndrome. Biol Psychiatry. 2004;55:89S.

48.  Sachdev PS. A rating scale for neuroleptic malignant syndrome. Psychiatry Res. 2005;135:249-256.

• 摘要

49.  Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome. Br J Psychiatry. 1991;159:709-712.

• 摘要

50.  Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry. 1999;33:650-659.

• 摘要

51.  Ozer F, Meral H, Aydin B, et al. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J ECT. 2005;21:125-127.

• 摘要

52.  Davis JM, Janicak PG, Sakkas P, et al. Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome. Convuls Ther. 1991;7:111-120.

• 摘要

53.  Scheftner WA, Shulman RB. Treatment choice in neuroleptic malignant syndrome. Convuls Ther. 1992;8:267-279.

• 摘要

54.  Adityanjee, Sajatovic M, Munshi KR. Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clin Neuropharmacol. 2005;28:197-204.

• 摘要